Latanoprost topique 0,1 %

Table2. Comparisonbetweenthedegreeofimprovementofdifferenttherapeuticgroupsandcontrolregardingglobalassessment. GroupI GroupII Groupsefficacy No. % No. % No. A0 8 40 4 20 6 A1 0 0 2 10 0 A2 2 10 0 0 2 A3 4 20 2 10 2 A4 2 10 4 20 4 A5 4 20 8 40 6 GroupIII GroupIV GroupV % No. % No. % pvalue (cid:3) 30 0 0 16 80 .001 (cid:3) 0 2 10 2 10 .027 (cid:3) 10 2 10 2 10 .003 (cid:3) 10 4 20 0 0 .001 (cid:3) 20 6 30 0 0 .001

El-Ashmawy AA, El-Maadawy IH, El-Maghraby GM. Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata.. J Dermatolog Treat 2018, DOI 10.1080/09546634.2017.1330527. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The anagen/telogen ra- tio decreased from 1.98 to 1.57 (P = .03) at the latanoprost-treated site. At the placebo-treated site, the ratio decreased from 2.28 to 1.67 (P = .1). The investigationalsitesshowednodifferenceatbaseline (P=.5)or24weeks(P=.6).

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Atthelatanoprost-treatedsite,theterminal/vellus ratiodecreasedfrom16.26to11.28(P=.1)andatthe placebo-treated site from 16.77 to 14.35 (P = .4). Therewasnodifferenceattheinvestigationalsitesat baseline(P=.8)or24weeks(P=.3).

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table2. Comparisonbetweenthedegreeofimprovementofdifferenttherapeuticgroupsandcontrolregardingglobalassessment. GroupI GroupII Groupsefficacy No. % No. % No. A0 8 40 4 20 6 A1 0 0 2 10 0 A2 2 10 0 0 2 A3 4 20 2 10 2 A4 2 10 4 20 4 A5 4 20 8 40 6 GroupIII GroupIV GroupV % No. % No. % pvalue (cid:3) 30 0 0 16 80 .001 (cid:3) 0 2 10 2 10 .027 (cid:3) 10 2 10 2 10 .003 (cid:3) 10 4 20 0 0 .001 (cid:3) 20 6 30 0 0 .001

El-Ashmawy AA, El-Maadawy IH, El-Maghraby GM. Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata.. J Dermatolog Treat 2018, DOI 10.1080/09546634.2017.1330527. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

50%goodclinicalresponse(8/16)(latanoprostbet- terthanplaceboat24weeksinatleasttwocriteria, orinonecriteriaalreadyat12,16,or20weeks). d 44%noclinicalresponse(7/16)(nodifferencesor inconsistent scores between latanoprost and placebo). d 6% bad clinical response (1/16) (placebo better than latanoprost at 24 weeks in at least two criteria, or in one criterion already at 12, 16, or 20 weeks).

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

A decrease of 5.1% in anagen hairs and increase in the telogen hair percentage were ob- servedatthelatanoprost-treatedsite(P=.02).Atthe placebo-treated site, a decrease of 5.6% in anagen hairs was observed, and conversely, an increase in thetelogenhairpercentage(P=.08).Theinvestiga- tionalsitesshowednodifferenceatbaseline(P=.8) or24weeks(P=.9).

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

An increase was observed from 8 (19%, weeks onward P = .03) at the latanoprost- 122% (P\.001). treated site, reaching at 24 weeks The variations at the placebo-treated site remained relativelysmall(110%at24weeks)andstatistically insignificant.

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

An increase was observed from 8 (19%, weeks onward P = .03) at the latanoprost- 122% (P\.001). treated site, reaching at 24 weeks The variations at the placebo-treated site remained relativelysmall(110%at24weeks)andstatistically insignificant.

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table II. Adverse effects observed over 24-week study period inall 16subjects Subject Adverseeffect Locatedat latanoprost-treated site A, B,C,F,M Erythema n=5 E Folliculitis n=1 Locatedat 2investigational sites F Sensationofbilateral n=1 burning Locatedoutside investigational sites G Erysipelas n=1

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table II. Adverse effects observed over 24-week study period inall 16subjects Subject Adverseeffect Locatedat latanoprost-treated site A, B,C,F,M Erythema n=5 E Folliculitis n=1 Locatedat 2investigational sites F Sensationofbilateral n=1 burning Locatedoutside investigational sites G Erysipelas n=1

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table II. Adverse effects observed over 24-week study period inall 16subjects Subject Adverseeffect Locatedat latanoprost-treated site A, B,C,F,M Erythema n=5 E Folliculitis n=1 Locatedat 2investigational sites F Sensationofbilateral n=1 burning Locatedoutside investigational sites G Erysipelas n=1

Blume-Peytavi U, Lönnfors S, Hillmann K et al.. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. Journal of the American Academy of Dermatology 2012, DOI 10.1016/j.jaad.2011.05.026. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).